Research progress of targeted cancer-associated fibroblast strategy for pancreatic ductal adenocarcinoma immunotherapy
10.3969/j.issn.1005-4847.2024.11.012
- VernacularTitle:靶向CAF策略在PDAC免疫治疗中的应用研究进展
- Author:
Xingyu LIU
1
;
Jing QIN
;
Yaohua HU
;
Mengtian GUO
;
Jumei ZHAO
;
Changhong SHI
Author Information
1. 延安大学基础医学院,陕西延安 716000;空军军医大学实验动物中心,西安 710032
- Publication Type:Journal Article
- Keywords:
pancreatic ductal adenocarcinoma;
cancer-associated fibroblast;
immunotherapy;
cytokine;
chemokine;
extracellular matrix
- From:
Acta Laboratorium Animalis Scientia Sinica
2024;32(11):1472-1481
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic ductal adenocarcinoma(PDAC)is a common type of pancreatic cancer that is insidious,develops rapidly,and is highly malignant.Traditional treatment strategies are ineffective for PDAC because of its rich extracellular matrix(ECM).Cancer-associated fibroblast(CAF)are the most important component of the ECM,and interact with other immune components in the tumor microenvironment(TME)by secreting numerous effector molecules to form an immunosuppressive TME,which may then allow cancer cells to evade immune system surveillance,promote tumor growth,invasion,and metastasis,and induce ECM remodeling and drug resistance.This review summarizes research progress on the application of targeted CAF in PDAC immunotherapy.We focus on exploring research strategies that promote the transition of TME from an immunosuppressive to an immune-activated state through depleting CAF,inhibiting effector molecules secreted by CAF,reprogramming CAF,and limiting CAF-induced ECM remodeling.This review aims to support the production of more effective therapeutic strategies and provide new method for the immunotherapy of PDAC.
